From: Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer
Disease response
ICM (n = 7)
ICM/VA (n = 9)
p-Value
Complete response, n (%)
0
NA
Partial response, n (%)
3 (33.3)
0.21
Stable disease, n (%)
2 (28.6)
2 (22.2)
Progressive disease, n (%)
5 (71.4)
4 (44.4)
0.36